1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 Ubunyulu >98.0% (HPLC) Brexpiprazole Intermediate Factory
Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-enye CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3
Igama leMchiza | 1-(1-Benzothiophen-4-yl) piperazine Hydrochloride |
Izithethantonye | I-Brexpiprazole ePhakathi 2;1-Benzo[b]thien-4-yl-Piperazine Hydrochloride;I-1-Benzo[b]thien-4-ylpiperazine Monohydrochloride |
Inombolo yeCAS | 913614-18-3 |
Inombolo yeCAT | RF-PI1034 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ye-100MT/Unyaka |
Ifomula yeemolekyuli | I-C12H15ClN2S |
Ubunzima beMolekyuli | 254.7789 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
Ukuchongwa | Ixesha lokugcinwa kwesampulu lihambelana nelo lomgangatho wereferensi |
Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
Ilahleko ekomisweni | <0.50% |
Amanzi (KF) | <0.50% |
Intsalela kwi-Ignition | <0.20% |
Izinto ezinxulumeneyo | (HPLC) |
Nakuphi na Ukungacoceki komntu | <0.50% |
Ukungcola ngokupheleleyo | <1.00% |
I-Infrared Spectrum | Iyahambelana noLwakhiwo |
Proton NMR Spectrum | Iyahambelana noLwakhiwo |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Umbindi weBrexpiprazole (CAS: 913611-97-9) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-1-(1-Benzothiophen-4-yl) piperazine Hydrochloride (CAS: 913614-18-3) iphakathi kweBrexpiprazole (CAS: 913611-97-9).I-Brexpiprazole luhlobo lwe-antipsychotic engabonakaliyo.Yi-dopamine D2 receptor partial agonist.Njengenoveli yemodyuli ye-serotonin-dopamine, inokusetyenziselwa unyango lwe-schizophrenia, kunye nonyango olongezelelweyo loxinzelelo.Inokubonelela ngokusebenza kunye nokunyamezeleka ngaphezu konyango olumiselweyo olunxulumene noxinzelelo olukhulu (MDD).Ichiza libonisa iphrofayili ekhethekileyo ye-pharmacological, esebenza njenge-agonist inxalenye ye-serotonin 5-HT1A kunye ne-dopamine D2 receptors kunye ne-antagonist epheleleyo ye-5-HT2A kunye ne-noradrenaline α1B / 2C i-receptors, kunye ne-subnanomolar efanayo ebophelelayo.Ichiza, elaphuhliswa ngu-Otsuka kunye no-Lundbeck, livunyiwe kwi-2015 yi-FDA yonyango lwe-schizophrenia kunye nonyango lokuncedisa ukudakumba.